These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30425069)

  • 101. Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
    Kumar SK; Callander NS; Alsina M; Atanackovic D; Biermann JS; Chandler JC; Costello C; Faiman M; Fung HC; Gasparetto C; Godby K; Hofmeister C; Holmberg L; Holstein S; Huff CA; Kassim A; Liedtke M; Martin T; Omel J; Raje N; Reu FJ; Singhal S; Somlo G; Stockerl-Goldstein K; Treon SP; Weber D; Yahalom J; Shead DA; Kumar R
    J Natl Compr Canc Netw; 2017 Feb; 15(2):230-269. PubMed ID: 28188192
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Treatment of multiple myeloma: 2009 update.
    Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
    [TBL] [Abstract][Full Text] [Related]  

  • 103. [Not Available].
    Z Gastroenterol; 2021 May; 59(5):493-494. PubMed ID: 34224130
    [No Abstract]   [Full Text] [Related]  

  • 104. Reply to N. Biran et al.
    Lonial S; Dhodapkar MV; Rajkumar SV
    J Clin Oncol; 2020 Apr; 38(12):1368-1369. PubMed ID: 32160076
    [No Abstract]   [Full Text] [Related]  

  • 105. The genomic features associated with high-risk multiple myeloma.
    Walker BA; Morgan GJ
    Oncotarget; 2018 Oct; 9(84):35478-35479. PubMed ID: 30464803
    [No Abstract]   [Full Text] [Related]  

  • 106. Plasma cell proliferative index is an independent predictor of progression in smoldering multiple myeloma.
    Aljama MA; Sidiqi MH; Lakshman A; Dispenzieri A; Jevremovic D; Gertz MA; Lacy MQ; Buadi FK; Dingli D; Muchtar E; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Warsame R; Kourelis TV; Hwa YL; Kapoor P; Leung N; Go RS; Kyle RA; Rajkumar SV; Kumar SK
    Blood Adv; 2018 Nov; 2(22):3149-3154. PubMed ID: 30463914
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
    Cohen OC; Counsell N; Rabin N; Popat R; Owen RG; Popova B; Schofield O; Clifton-Hadley L; Lyons-Lewis J; Rawstron A; Spence C; de Tute RM; Hughes D; Moore S; Smith P; Yong KL
    Br J Haematol; 2019 Jun; 185(5):948-951. PubMed ID: 30460696
    [No Abstract]   [Full Text] [Related]  

  • 108. Autologous graft versus myeloma: it's not a myth.
    Dong S; Ghobrial IM
    J Clin Invest; 2019 Jan; 129(1):48-50. PubMed ID: 30457981
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma.
    Ravi P; Kumar SK; Roeker L; Gonsalves W; Buadi F; Lacy MQ; Go RS; Dispenzieri A; Kapoor P; Lust JA; Dingli D; Lin Y; Russell SJ; Leung N; Gertz MA; Kyle RA; Bergsagel PL; Rajkumar SV
    Blood Cancer J; 2018 Nov; 8(12):116. PubMed ID: 30442928
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Venetoclax for the treatment of multiple myeloma.
    Vaxman I; Sidiqi MH; Gertz M
    Expert Rev Hematol; 2018 Dec; 11(12):915-920. PubMed ID: 30428277
    [No Abstract]   [Full Text] [Related]  

  • 111. Design and Rationale of Prolonged Nightly Fasting for Multiple Myeloma Prevention (PROFAST): Protocol for a Randomized Controlled Pilot Trial.
    Lee DJ; O'Donnell EK; Raje N; Panaroni C; Redd R; Ligibel J; Sears DD; Nadeem O; Ghobrial IM; Marinac CR
    JMIR Res Protoc; 2024 Mar; 13():e51368. PubMed ID: 38466984
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma.
    Brighton TA; Khot A; Harrison SJ; Ghez D; Weiss BM; Kirsch A; Magen H; Gironella M; Oriol A; Streetly M; Kranenburg B; Qin X; Bandekar R; Hu P; Guilfoyle M; Qi M; Nemat S; Goldschmidt H
    Clin Cancer Res; 2019 Jul; 25(13):3772-3775. PubMed ID: 30890552
    [TBL] [Abstract][Full Text] [Related]  

  • 113. State of the science in smoldering myeloma: Should we be treating in the clinic?
    Hill E; Dew A; Kazandjian D
    Semin Oncol; 2019 Apr; 46(2):112-120. PubMed ID: 31072611
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Risk Stratification and Treatment in Smoldering Multiple Myeloma.
    Lussier T; Schoebe N; Mai S
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011692
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Timing of treatment of smoldering myeloma: delay until progression.
    Kumar SK
    Blood Adv; 2018 Nov; 2(21):3050-3053. PubMed ID: 30425069
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Timing of treatment of smoldering myeloma: early treatment.
    Mateos MV; González-Calle V
    Blood Adv; 2018 Nov; 2(21):3045-3049. PubMed ID: 30425068
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS).
    Landgren CO; Chari A; Cohen YC; Spencer A; Voorhees P; Estell JA; Sandhu I; Jenner MW; Williams C; Cavo M; van de Donk NWCJ; Beksac M; Moreau P; Goldschmidt H; Kuppens S; Bandekar R; Clemens PL; Neff T; Heuck C; Qi M; Hofmeister CC
    Leukemia; 2020 Jul; 34(7):1840-1852. PubMed ID: 32024950
    [TBL] [Abstract][Full Text] [Related]  

  • 118.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 119.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 120.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.